Blood Panel 50+ & Biological Age Testing

REGEVITA's Blood Panel 50+ and biological age testing service combines a comprehensive blood chemistry screen targeted at adult health priorities — cardiovascular markers, hormonal balance, organ function, inflammatory load — with a biological age assessment to reveal the gap between a patient's chronological and physiological age. The panel is designed by the clinic's internist Dr. Yaroslav Kuzminskyi as both a diagnostic baseline and a personalised longevity roadmap: results identify which organ systems are performing below age-expected norms and guide the clinic's subsequent recommendations on IV therapy, lifestyle, hormone optimisation, and supplementation. For patients embarking on a longevity programme, this panel serves as the starting point from which progress is measured.

REGEVITA's Blood Panel 50+ was designed for adults who want more than a standard annual check-up — it extends routine biochemistry with the markers most relevant to mid-life and longevity medicine, and layers in biological age assessment to give patients a concrete, data-driven picture of how well their body is ageing relative to their calendar years. The panel addresses the four most clinically significant domains in preventive internal medicine for adults over 40: cardiovascular risk (lipid profile including LDL particle size if available, homocysteine, hs-CRP as an independent risk marker, fibrinogen), metabolic and hormonal health (fasting glucose, HbA1c, insulin, HOMA-IR for insulin resistance; testosterone and DHEA-S for hormonal status; thyroid panel — TSH, fT3, fT4), organ function (liver enzymes ALT, AST, GGT, bilirubin; kidney function via creatinine, eGFR, uric acid; haematological status via CBC), and inflammation and micronutrient status (ferritin, vitamin D, B12, magnesium, zinc, hs-CRP). The biological age assessment component uses validated composite biomarker algorithms — drawing on inflammatory, metabolic, and epigenetic-proxy markers from the blood draw — to compute a physiological age estimate. This provides an objective anchor for the clinic's longevity programme: patients whose biological age exceeds chronological age by more than three to five years are typically prioritised for early intervention with ozone, NAD+, or targeted nutritional infusion protocols. Results are reviewed by Dr. Kuzminskyi in a dedicated consultation, during which the physician translates laboratory values into actionable recommendations. Patients with borderline testosterone may be assessed for natural supplementation options before pharmaceutical intervention is considered. The panel is typically repeated every six months for patients on active longevity protocols and annually for those in maintenance phase. Standard pre-draw fasting of 10–12 hours is recommended; water is permitted.